ALLIANCE-MM1MDS-A01
Phase II
OPEN TO ACCRUAL
A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Sub-Study
ASCENTAGE-APG2575MG301-GLORA-4
Phase III
OPEN TO ACCRUAL
A Global Multicenter, Double-Blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-2575) in Combination With Azacitidine (AZA) in Patients With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4)
BEIGENE-BGB-11417-103
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients with Myeloid Malignancies
DISC-0974-102
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia
IIT-GURU-IADADEMSTAT-MDS
Phase I
OPEN TO ACCRUAL
Phase I Study of Iadademstat with Hypomethylating Agent in Patients with Myelodysplastic Syndrome
INNOCARE-ICP-CL-01205
Phase I
OPEN TO ACCRUAL
A Phase 1 Study of ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies